- Home
- ATAI vs AQST Comparison
ATAI vs AQST Comparison
Compare ATAI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- AQST
- Stock Information
- Founded
- ATAI 2018
- AQST 2004
- Country
- ATAI Germany
- AQST United States
- Employees
- ATAI N/A
- AQST N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- AQST Health Care
- Exchange
- ATAI Nasdaq
- AQST Nasdaq
- Market Cap
- ATAI 282.6M
- AQST 254.1M
- IPO Year
- ATAI 2021
- AQST 2018
- Fundamental
- Price
- ATAI $1.41
- AQST $2.76
- Analyst Decision
- ATAI Strong Buy
- AQST Strong Buy
- Analyst Count
- ATAI 3
- AQST 5
- Target Price
- ATAI $10.50
- AQST $11.40
- AVG Volume (30 Days)
- ATAI 1.4M
- AQST 984.2K
- Earning Date
- ATAI 05-19-2025
- AQST 05-12-2025
- Dividend Yield
- ATAI N/A
- AQST N/A
- EPS Growth
- ATAI N/A
- AQST N/A
- EPS
- ATAI N/A
- AQST N/A
- Revenue
- ATAI $308,000.00
- AQST $57,561,000.00
- Revenue This Year
- ATAI $65.58
- AQST N/A
- Revenue Next Year
- ATAI N/A
- AQST $39.51
- P/E Ratio
- ATAI N/A
- AQST N/A
- Revenue Growth
- ATAI N/A
- AQST 13.79
- 52 Week Low
- ATAI $1.03
- AQST $2.20
- 52 Week High
- ATAI $2.57
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- ATAI 44.57
- AQST 48.51
- Support Level
- ATAI $1.36
- AQST $2.65
- Resistance Level
- ATAI $1.54
- AQST $3.05
- Average True Range (ATR)
- ATAI 0.09
- AQST 0.16
- MACD
- ATAI -0.00
- AQST 0.00
- Stochastic Oscillator
- ATAI 0.00
- AQST 50.51
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.